

170
81
9/4/02

VIA FACSIMILE SEPTEMBER 4th, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OIC to enlin
PM 9/4/02

In re application of: SU et al.

Application Serial No.: 09/416,267

Art Unit: 1646

Filed: October 12, 1999

Examiner: Mertz, P.

For: Human Cytokine Polypeptide

Attorney Docket No.: PF270P1

SUPPLEMENTAL RESPONSE UNDER 37 C.F.R. § 1.116

Commissioner for Patents

Washington, D.C. 20231

Sir

In response to the concerns raised by the Examiner in a telephone conversation of September 3, 2002, with the undersigned, please enter the following amendments and consider the enclosed remarks. Submitted concurrently herewith is: (a) a Fee Transmittal sheet; (b) a Version With Markings Showing Changes Made; and (c) a copy of the Associate Power of Attorney previously submitted in this application on September 4, 2001.

Prior to further examination, please amend the application as follows:

In the Claims:

Please replace pending claims 32, 41, 50, 59, 66 and 78 with the following rewritten claims:

D1

8
32. (Once Amended) A composition comprising the isolated protein of claim 1 and an acceptable carrier.